reports
AMN Healthcare Announces First Quarter 2024 Results
AMN Healthcare Announces First Quarter 2024 Results Quarterly revenue of $821 million; GAAP EPS of $0.45 and adjusted EPS of $0.97 DALLAS, May 09, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2024 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts. Q1 2024% Change Q1 2023Revenue$820.9(27%) Gross profit$257.5(30%) Net income$17.3(79%) GAAP diluted EPS$0.45(78%) Adjusted dilute...
Tyson Foods Announces Quarterly Dividend
Tyson Foods Announces Quarterly Dividend SPRINGDALE, Ark., May 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Tyson Foods (NYSE: TSN), at a meeting on May 9, 2024, declared a quarterly dividend of $0.49 per share on Class A common stock and $0.441 per share on Class B common stock, payable on September 13, 2024, to shareholders of record at the close of business on August 30, 2024. About Tyson Foods, Inc.Tyson Foods, Inc. (NYSE: TSN) is a world-class food company and recognized leader in protein. Founded in 1935 by John W. Tyson, it has grown under four generations of family lead...
- Wedbush Research
MTB M&T BANK CORPORATION
STZ CONSTELLATION BRANDS INC. CLASS A
UBI UBISOFT ENTERTAINMENT SA
DPZ DOMINO'S PIZZA INC.
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PEGA PEGASYSTEMS INC.
MGPI MGP INGREDIENTS INC.
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FHN FIRST HORIZON CORPORATION
EPAM EPAM SYSTEMS INC.
DECK DECKERS OUTDOOR CORPORATION
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
OSTK OVERSTOCK.COM INC.
WD WALKER & DUNLOP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
TENB TENABLE HOLDINGS
BROS DUTCH BROS INC
Sterling Reports First Quarter 2024 Results
Sterling Reports First Quarter 2024 Results Strong Revenue Results, including Organic Growth from New Business, Up/Cross-Sell, and Customer Attrition INDEPENDENCE, Ohio, May 09, 2024 (GLOBE NEWSWIRE) -- Sterling Check Corp. (NASDAQ: STER) (“Sterling” or “the Company”) a leading global provider of technology-enabled background and identity verification services, today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights All results compared to prior-year period. Revenues increased 3.8% year-over-year to $18...
Walker & Dunlop Inc: 1 director
A director at Walker & Dunlop Inc sold 4,533 shares at 97.330USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Nutrien Announces Results of 2024 Annual Meeting
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- Nutrien Ltd. (TSX and NYSE: NTR) announced today the results of its annual meeting of shareholders held on May 8, 2024 (the “Meeting”). A total of 369,251,444 common shares, representing 74.66% of common shares outstanding, were represented at the Meeting. Results of the matters voted on at the Meeting are set out below. Election of Directors Nutrien’s 12 director nominees were elected: Votes For (percent) Votes Against (percent) Christopher M. Burley 98.33% 1.67% Maura J. Clark 98.95% 1.05% ...
Nutrien Declares Quarterly Dividend of US$0.54 per Share
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- Nutrien Ltd. (TSX and NYSE: NTR) announced today that its Board of Directors has declared a quarterly dividend of US$0.54 per share payable on July 19, 2024, to shareholders of record on June 28, 2024. Registered shareholders who are residents of Canada as reflected in Nutrien's shareholders register, as well as beneficial holders (i.e., shareholders who hold their common shares through a broker or other intermediary) whose intermediary is a participant in CDS Clearing and Depositary Services Inc. or its nominee, CDS & Co., will receive their divide...
Nutrien Reports First Quarter 2024 Results
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- Nutrien Ltd. (TSX and NYSE: NTR) announced today its first quarter 2024 results, with net earnings of $165 million ($0.32 diluted net earnings per share). First quarter 2024 adjusted EBITDA1 was $1.1 billion and adjusted net earnings per share1 was $0.46. “We continued to see strong crop input demand, a normalization of product margins for our North American Retail business and increased global potash shipments in the first quarter. Our results highlighted the capabilities of our flexible, low-cost production assets and downstream distribution netwo...
Leslie’s, Inc. Announces Second Quarter Fiscal 2024 Financial Results
Leslie’s, Inc. Announces Second Quarter Fiscal 2024 Financial Results Sales of $188.7 millionNet Loss of $34.6 millionAdjusted EBITDA of $(19.3) million Diluted earnings per share of $(0.19); Adjusted diluted earnings per share of $(0.17)Company reaffirms fiscal 2024 outlook PHOENIX, May 08, 2024 (GLOBE NEWSWIRE) -- Leslie’s, Inc. (“Leslie’s”, “we”, “our”, “its”, or “Company”; NASDAQ: LESL), the largest and most trusted direct-to-consumer brand in the U.S. pool and spa care industry, today announced its financial results for the second quarter of fiscal 2024. Mike Egeck, Chief...
Verve Therapeutics Announces Pipeline Progress and Reports First Quart...
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102 VERVE-201 clinical trial initiation on track for the second half of 2024 Received first milestone payment from Eli Lilly for collaboration on an in vivo gene editing program targeting lipoprotein(a) (Lp(a)) Cash, cash equivalents and marketable securities of $606.4 million; cash runway into late 2026 BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- , a clinical-stage biotechnology company pioneering a new approach to the care of ca...
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global He...
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2024 Global Healthcare Conference on Wednesday, May 15, 2024, at 1:35 p.m. ET in New York City. A live webcast will be available in the investor section of the company's website at , and will be archived for 60 day...
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase ...
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 VERVE-102 is an investigational in vivo base editing medicine designed to permanently inactivate the PCSK9 gene in the liver to durably reduce blood low-density lipoprotein cholesterol Heart-2 enrolling patients with heterozygous familial hypercholesterolemia or premature coronary artery disease BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines...
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Fina...
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM-301 On Track for Submission of U.S. Investigational New Drug (IND) Application in First Half of 2024 Ended First Quarter 2024 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runw...
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Jonathan Moreland
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
LTRX LANTRONIX INC.
HXL HEXCEL CORPORATION
HOO HERBALIFE NUTRITION LTD.
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
EAF GRAFTECH INTERNATIONAL
GH GUARDANT HEALTH
DNA GINKGO BIOWORKS HOLDINGS
TBBK INC.
RXO_w THE BANCORP
VSTS_w INC.
CFFI RXO INC
RENT VESTIS CORPORATION
C&F FINANCIAL CORPORATION
RENT THE RUNWAY INC
Essex Property Trust Publishes Sixth Annual ESG Report
SAN MATEO, Calif.--(BUSINESS WIRE)-- Essex Property Trust, Inc. (NYSE:ESS) announces the publication of its 2023 Environmental, Social, and Governance (“ESG”) Report which highlights the Company’s notable progress towards its goals introduced in its 2022 ESG Report, improved benchmark scores, and our recent commitment to setting science-based, near-term greenhouse gas (“GHG”) reduction targets through the Science Based Targets initiative (“SBTi”). “Over the last several years, our residents, employees, and shareholders have been experiencing continuous transformation in the workplace and eco...
Survey: Nurses See Little Improvement in 2024
Survey: Nurses See Little Improvement in 2024 Over One-Third Extremely Likely to Change Jobs DALLAS, May 06, 2024 (GLOBE NEWSWIRE) -- The majority of nurses (80%) think 2024 will be either no better or worse for nurses than 2023, according to a new survey by AMN Healthcare, the nation’s leading healthcare workforce solutions company. Forty-two percent said 2024 will be the same for nurses as 2023, 38% said it will be worse, while only 20% said it will be better. “Nurses weathered the storm of COVID-19, but many still see clouds ahead for the profession,” said Robin Johnson, Group Presi...
Allogene Therapeutics to Report First Quarter Financial Results and Pr...
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report first quarter 2024 financial results and provide a business update on May 13, 2024, after the close of the market. The announcement w...
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablati...
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizes SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data show...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.